Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 11/20 | 0.55 |
| ▸ | CCR2 | P41597 | 2/20 | 0.55 |
| ▸ | CCR7 | P32248 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | CCR4 | P51679 | 1/20 | 0.52 |
| ▸ | RARB | P10826 | 6/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17870869 | 1.00 | CCR5 (0.55) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3163971 | 0.95 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3163964 | 0.95 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3459366 | 0.93 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3459367 | 0.93 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3459362 | 0.93 | CCR5 (0.61) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3459699 | 0.93 | CCR5 (0.56) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL3459703 | 0.93 | CCR5 (0.56) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL17870843 | 0.92 | CCR5 (0.53) | CCR5CCR2CCR7CCR3CCR4 | |
| SCHEMBL17870844 | 0.92 | CCR5 (0.53) | CCR5CCR2CCR7CCR3CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | claimed |
| EP-3471718-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | Tobira Therapeutics, Inc. (US) | 2019-04-24 | — | — | EP | claimed |
| US-20180327428-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2018-11-15 | — | — | US | claimed |
| WO-2017223155-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS, INC. (US) | 2017-12-28 | — | — | WO | claimed |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS INC (US) | 2017-12-21 | — | — | US | claimed |
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200095229-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS INC (US) | 2020-03-26 | — | — | US | disclosed |
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3471718-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | Tobira Therapeutics, Inc. (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180327428-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2018-11-15 | — | — | US | disclosed |
| WO-2017223155-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS INC (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3237424-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | Tobira Therapeutics, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016105527-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327428-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | CCR5, CCR2, CCR3 | CCR5 1/4885CCR2 2/4885CCR7 14/4885 |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | CCR5, CCR2, CCR3 | CCR5 1/4885CCR2 2/4885CCR7 14/4885 |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | CCR5, CCR2, CXCR3 | CCR5 1/4885CCR2 2/4885CCR7 12/4885 |
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | CCR5 1/4885CCR2 2/4885CCR7 12/4885 |
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | CCR5 1/4885CCR2 2/4885CCR7 12/4885 |
| US-20200095229-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | CCR5 1/4885CCR2 2/4885CCR7 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.